Single User License
INR 168725
Site License
INR 337450
Corporate User License
INR 506175

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Breast Cancer-Pipeline Review, H1 2015

Breast Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Breast Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Breast Cancer-Pipeline Review, H1 2015', provides an overview of the Breast Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Breast Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Breast Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 16

Breast Cancer Overview 17

Therapeutics Development 18

Breast Cancer-Therapeutics under Development by Companies 20

Breast Cancer-Therapeutics under Investigation by Universities/Institutes 51

Breast Cancer-Pipeline Products Glance 60

Breast Cancer-Products under Development by Companies 64

Breast Cancer-Products under Investigation by Universities/Institutes 111

Breast Cancer-Companies Involved in Therapeutics Development 122

Breast Cancer-Therapeutics Assessment 468

Drug Profiles 510

Breast Cancer-Recent Pipeline Updates 1716

Breast Cancer-Dormant Projects 2169

Breast Cancer-Discontinued Products 2208

Breast Cancer-Product Development Milestones 2219

Appendix 2231

List of Tables

Number of Products under Development for Breast Cancer, H1 2015 103

Number of Products under Development for Breast Cancer-Comparative Analysis, H1 2015 104

Number of Products under Development by Companies, H1 2015 106

Number of Products under Development by Companies, H1 2015 (Contd..1) 107

Number of Products under Development by Companies, H1 2015 (Contd..2) 108

Number of Products under Development by Companies, H1 2015 (Contd..3) 109

Number of Products under Development by Companies, H1 2015 (Contd..4) 110

Number of Products under Development by Companies, H1 2015 (Contd..5) 111

Number of Products under Development by Companies, H1 2015 (Contd..6) 112

Number of Products under Development by Companies, H1 2015 (Contd..7) 113

Number of Products under Development by Companies, H1 2015 (Contd..8) 114

Number of Products under Development by Companies, H1 2015 (Contd..9) 115

Number of Products under Development by Companies, H1 2015 (Contd..10) 116

Number of Products under Development by Companies, H1 2015 (Contd..11) 117

Number of Products under Development by Companies, H1 2015 (Contd..12) 118

Number of Products under Development by Companies, H1 2015 (Contd..13) 119

Number of Products under Development by Companies, H1 2015 (Contd..14) 120

Number of Products under Development by Companies, H1 2015 (Contd..15) 121

Number of Products under Development by Companies, H1 2015 (Contd..16) 122

Number of Products under Development by Companies, H1 2015 (Contd..17) 123

Number of Products under Development by Companies, H1 2015 (Contd..18) 124

Number of Products under Development by Companies, H1 2015 (Contd..19) 125

Number of Products under Development by Companies, H1 2015 (Contd..20) 126

Number of Products under Development by Companies, H1 2015 (Contd..21) 127

Number of Products under Development by Companies, H1 2015 (Contd..22) 128

Number of Products under Development by Companies, H1 2015 (Contd..23) 129

Number of Products under Development by Companies, H1 2015 (Contd..24) 130

Number of Products under Development by Companies, H1 2015 (Contd..25) 131

Number of Products under Development by Companies, H1 2015 (Contd..26) 132

Number of Products under Development by Companies, H1 2015 (Contd..27) 133

Number of Products under Development by Companies, H1 2015 (Contd..28) 134

Number of Products under Development by Companies, H1 2015 (Contd..29) 135

Number of Products under Investigation by Universities/Institutes, H1 2015 137

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 138

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 139

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 140

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 141

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 142

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 143

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 144

Comparative Analysis by Late Stage Development, H1 2015 145

Comparative Analysis by Clinical Stage Development, H1 2015 146

Comparative Analysis by Early Stage Development, H1 2015 147

Comparative Analysis by Unknown Stage Development, H1 2015 148

Products under Development by Companies, H1 2015 149

Products under Development by Companies, H1 2015 (Contd..1) 150

Products under Development by Companies, H1 2015 (Contd..2) 151

Products under Development by Companies, H1 2015 (Contd..3) 152

Products under Development by Companies, H1 2015 (Contd..4) 153

Products under Development by Companies, H1 2015 (Contd..5) 154

Products under Development by Companies, H1 2015 (Contd..6) 155

Products under Development by Companies, H1 2015 (Contd..7) 156

Products under Development by Companies, H1 2015 (Contd..8) 157

Products under Development by Companies, H1 2015 (Contd..9) 158

Products under Development by Companies, H1 2015 (Contd..10) 159

Products under Development by Companies, H1 2015 (Contd..11) 160

Products under Development by Companies, H1 2015 (Contd..12) 161

Products under Development by Companies, H1 2015 (Contd..13) 162

Products under Development by Companies, H1 2015 (Contd..14) 163

Products under Development by Companies, H1 2015 (Contd..15) 164

Products under Development by Companies, H1 2015 (Contd..16) 165

Products under Development by Companies, H1 2015 (Contd..17) 166

Products under Development by Companies, H1 2015 (Contd..18) 167

Products under Development by Companies, H1 2015 (Contd..19) 168

Products under Development by Companies, H1 2015 (Contd..20) 169

Products under Development by Companies, H1 2015 (Contd..21) 170

Products under Development by Companies, H1 2015 (Contd..22) 171

Products under Development by Companies, H1 2015 (Contd..23) 172

Products under Development by Companies, H1 2015 (Contd..24) 173

Products under Development by Companies, H1 2015 (Contd..25) 174

Products under Development by Companies, H1 2015 (Contd..26) 175

Products under Development by Companies, H1 2015 (Contd..27) 176

Products under Development by Companies, H1 2015 (Contd..28) 177

Products under Development by Companies, H1 2015 (Contd..29) 178

Products under Development by Companies, H1 2015 (Contd..30) 179

Products under Development by Companies, H1 2015 (Contd..31) 180

Products under Development by Companies, H1 2015 (Contd..32) 181

Products under Development by Companies, H1 2015 (Contd..33) 182

Products under Development by Companies, H1 2015 (Contd..34) 183

Products under Development by Companies, H1 2015 (Contd..35) 184

Products under Development by Companies, H1 2015 (Contd..36) 185

Products under Development by Companies, H1 2015 (Contd..37) 186

Products under Development by Companies, H1 2015 (Contd..38) 187

Products under Development by Companies, H1 2015 (Contd..39) 188

Products under Development by Companies, H1 2015 (Contd..40) 189

Products under Development by Companies, H1 2015 (Contd..41) 190

Products under Development by Companies, H1 2015 (Contd..42) 191

Products under Development by Companies, H1 2015 (Contd..43) 192

Products under Development by Companies, H1 2015 (Contd..44) 193

Products under Development by Companies, H1 2015 (Contd..45) 194

Products under Development by Companies, H1 2015 (Contd..46) 195

Products under Investigation by Universities/Institutes, H1 2015 196

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 197

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 198

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 199

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 200

Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 201

Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 202

Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 203

Products under Investigation by Universities/Institutes, H1 2015 (Contd..8) 204

Products under Investigation by Universities/Institutes, H1 2015 (Contd..9) 205

Products under Investigation by Universities/Institutes, H1 2015 (Contd..10) 206

Breast Cancer-Pipeline by 3-V Biosciences, Inc., H1 2015 207

Breast Cancer-Pipeline by A&G Pharmaceutical, Inc., H1 2015 208

Breast Cancer-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 209

Breast Cancer-Pipeline by AB Science, H1 2015 210

Breast Cancer-Pipeline by AbbVie Inc., H1 2015 211

Breast Cancer-Pipeline by AbGenomics International, Inc., H1 2015 212

Breast Cancer-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 213

Breast Cancer-Pipeline by Adaptimmune Limited, H1 2015 214

Breast Cancer-Pipeline by Advanced Cancer Therapeutics, H1 2015 215

Breast Cancer-Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015 216

Breast Cancer-Pipeline by Advaxis, Inc., H1 2015 217

Breast Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 218

Breast Cancer-Pipeline by Aegis Therapeutics, LLC, H1 2015 219

Breast Cancer-Pipeline by Aerpio Therapeutics, Inc., H1 2015 220

Breast Cancer-Pipeline by Aeterna Zentaris Inc., H1 2015 221

Breast Cancer-Pipeline by Affichem, H1 2015 222

Breast Cancer-Pipeline by Aileron Therapeutics, Inc., H1 2015 223

Breast Cancer-Pipeline by Alchemia Limited, H1 2015 224

Breast Cancer-Pipeline by Alethia Biotherapeutics Inc., H1 2015 225

Breast Cancer-Pipeline by Almac Discovery Ltd., H1 2015 226

Breast Cancer-Pipeline by AlphaMab Co., Ltd, H1 2015 227

Breast Cancer-Pipeline by AlphaVax, Inc., H1 2015 228

Breast Cancer-Pipeline by Amarna Therapeutics B.V., H1 2015 229

Breast Cancer-Pipeline by Ambrx, Inc., H1 2015 230

Breast Cancer-Pipeline by Amgen Inc., H1 2015 231

Breast Cancer-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 232

List of Figures

Number of Products under Development for Breast Cancer, H1 2015 103

Number of Products under Development for Breast Cancer-Comparative Analysis, H1 2015 104

Number of Products under Development by Companies, H1 2015 105

Number of Products under Investigation by Universities/Institutes, H1 2015 136

Comparative Analysis by Late Stage Development, H1 2015 145

Comparative Analysis by Clinical Stage Development, H1 2015 146

Comparative Analysis by Early Stage Products, H1 2015 147

Assessment by Monotherapy Products, H1 2015 553

Assessment by Combination Products, H1 2015 554

Number of Products by Top 10 Targets, H1 2015 555

Number of Products by Stage and Top 10 Targets, H1 2015 555

Number of Products by Top 10 Mechanism of Actions, H1 2015 577

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 577

Number of Products by Top 10 Routes of Administration, H1 2015 591

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 591

Number of Products by Top 10 Molecule Types, H1 2015 593

Number of Products by Stage and Top 10 Molecule Types, H1 2015 593

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3-V Biosciences, Inc.

A&G Pharmaceutical, Inc.

A. Menarini Industrie Farmaceutiche Riunite Srl

AB Science

AbbVie Inc.

AbGenomics International, Inc.

Actinium Pharmaceuticals, Inc.

Adaptimmune Limited

Advanced Cancer Therapeutics

Advanced Proteome Therapeutics Corporation

Advaxis, Inc.

Advenchen Laboratories, LLC

Aegis Therapeutics, LLC

Aerpio Therapeutics, Inc.

Aeterna Zentaris Inc.

Affichem

Aileron Therapeutics, Inc.

Alchemia Limited

Alethia Biotherapeutics Inc.

Almac Discovery Ltd.

AlphaMab Co., Ltd

AlphaVax, Inc.

Amarna Therapeutics B.V.

Ambrx, Inc.

Amgen Inc.

Ampio Pharmaceuticals, Inc.

Amplyx Pharmaceuticals, Inc.

AngioGenex, Inc.

Angion Biomedica Corp.

AntiCancer, Inc.

Antigen Express, Inc.

Antoxis Limited

Aphios Corporation

Aptose Biosciences Inc.

Armour Therapeutics Inc.

Arno Therapeutics, Inc.

Arrien Pharmaceuticals, LLC

Ascenta Therapeutics, Inc.

Ascentage Pharma Group Corporation, Ltd.

AstraZeneca PLC

Aurigene Discovery Technologies Limited

AVEO Pharmaceuticals, Inc.

Avipep Pty Ltd

Axelar AB

Azaya Therapeutics Incorporated

Basilea Pharmaceutica AG

Bavarian Nordic A/S

Bayer AG

BBB Therapeutics B.V.

BerGenBio AS

BHR Pharma, LLC

Bio-Path Holdings, Inc.

BIOCAD

Biocon Limited

BioMarin Pharmaceutical Inc.

Bionomics Limited

BioNTech AG

BioNumerik Pharmaceuticals, Inc.

Bioo Therapeutics

BiOrion Technologies B.V.

Biotecnol, Inc.

Biotest AG

Biscayne Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Cancer Therapeutics CRC Pty Ltd

CASI Pharmaceuticals Inc.

Cavion LLC

CEL-SCI Corporation

Celgene Corporation

Cellceutix Corporation

Celldex Therapeutics, Inc.

Celltrion, Inc.

Celsion Corporation

Cerulean Pharma, Inc.

China Grand Wuhan General Pharmaceutical Research Institute

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp.

Chugai Pharmaceutical Co., Ltd.

Cimab S.A.

Clovis Oncology, Inc.

Cold Genesys, Inc.

Compugen Ltd.

Corcept Therapeutics Incorporated

Coronado Biosciences, Inc.

Covagen AG

Critical Outcome Technologies Inc.

CTI BioPharma Corp.

Curadev Pharma Private Limited

Curadis GmbH

Curaxys, S.L.

CureFAKtor Pharmaceuticals, LLC

Curis, Inc.

Cyclacel Pharmaceuticals, Inc.

CytomX Therapeutics, Inc.

CZ BioMed Corp

Daiichi Sankyo Company, Limited

Debiopharm International S.A.

Deciphera Pharmaceuticals, LLC

Dendreon Corporation

DexTech Medical AB

Digna Biotech, S.L.

DiNonA Inc.

Dompe Farmaceutici S.p.A.

Dong-A Socio Group

Dongkook Pharmaceutical Co., Ltd.

DormaTarg, Inc.

Egenix, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EndoCeutics, Inc.

Endocyte, Inc.

EntreChem, S.L.

Epigen Biosciences, Inc.

Epirus Biopharmaceuticals, Inc.

Erytech Pharma SA

Esperance Pharmaceuticals, Inc.

Etubics Corporation

Evgen Limited

Exelixis, Inc.

F-star Alpha Ltd.

F. Hoffmann-La Roche Ltd.

FibroStatin SL

FirstString Research, Inc.

G1 Therapeutics, Inc.

Galapagos NV

Galectin Therapeutics, Inc.

Galena Biopharma, Inc.

Galileo Research s.r.l.

Ganymed Pharmaceuticals AG

GeneFrontier Corporation

Genelux Corporation

Genentech, Inc.

Genor BioPharma Co., Ltd.

GenSpera, Inc.

GlaxoSmithKline plc

Glycotope GmbH

Green Cross Corporation

GTx, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

Hanwha Chemical Corporation

Harbor Therapeutics, Inc.

Heat Biologics, Inc.

Helix BioPharma Corp.

Hemispherx Biopharma, Inc.

Histogen, Inc.

Hospira, Inc.

Huabo Biopharm Co., Ltd.

Hutchison MediPharma Limited

Ignyta, Inc.

Ildong Pharmaceutical Co., Ltd.

Immune Design Corp.

ImmunoFrontier, Inc.

ImmunoGen, Inc.

Immunomedics, Inc.

Immunophotonics Inc

Immunovaccine, Inc.

Immunovative Therapies, Ltd.

IMPACT Therapeutics, Inc.

Imugene Limited

Inbiopro Solutions Pvt. Ltd.

Incuron, LLC

Incyte Corporation

Inovio Pharmaceuticals, Inc.

Intica Biomedical, Inc.

Invictus Oncology Pvt. Ltd.

Io Therapeutics, Inc.

Ipsen S.A.

Jasco Pharmaceuticals, LLC.

Jeil Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Johnson & Johnson

JW Pharmaceutical Corporation

Kadmon Corporation, LLC

Kalos Therapeutics, Inc.

Kancera AB

Keystone Nano, Inc.

Kinex Pharmaceuticals, LLC

Kyowa Hakko Kirin Co., Ltd.

Laboratoires Pierre Fabre SA

Laboratorio Elea S.A.C.I.F. and A

Laboratorios Farmaceuticos Rovi, S.A.

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

LivTech, Inc.

LondonPharma Ltd

Lytix Biopharma AS

Mabion SA

MacroGenics, Inc.

MandalMed, Inc.

Meabco A/S

Mebiopharm Co., Ltd.

MediaPharma s.r.l.

MedImmune, LLC

Medivation, Inc.

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Merrion Pharmaceuticals Plc

Merus B.V.

MetaStat, Inc.

Mission Therapeutics Ltd

Molecular Partners AG

Molecular Templates Inc.

Morphotek, Inc.

MultiCell Technologies, Inc.

Multimmune GmbH

Nanobiotix

NanoCarrier Co., Ltd.

Natco Pharma Limited

Nektar Therapeutics

Nemucore Medical Innovations, Inc.

Netherlands Translational Research Center B.V.

NewLink Genetics Corporation

Nexgenix Pharmaceuticals, LLC

Nexigen GmbH

Nippon Kayaku Co., Ltd.

Northwest Biotherapeutics, Inc.

Novartis AG

NuCana BioMed Limited

Oasmia Pharmaceutical AB

OBI Pharma, Inc.

Omnitura Therapeutics Inc.

Oncbiomune, L.L.C.

Oncobiologics, Inc.

OncoEthix SA

Oncogenex Pharmaceuticals, Inc.

Oncolix, Inc.

Oncology Research International Limited

Oncolytics Biotech Inc.

Oncomatrix, S.L.

OncoMax

OncoMed Pharmaceuticals, Inc.

Onconova Therapeutics, Inc.

Oncothyreon Inc.

Oncovir, Inc.

OncoVista Innovative Therapies, Inc.

Ono Pharmaceutical Co., Ltd.

Orega Biotech SAS

OSE Pharma SA

Otsuka Holdings Co., Ltd.

Oxford BioTherapeutics Ltd

OXiGENE, Inc.

Pacific Northwest Biotechnology, LLC

Panacea Biotec Limited

Pantarhei Bioscience BV

Paras Biopharmaceuticals Finland Oy

Patrys Limited

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Pharma Two B Ltd

Pharmacyclics, Inc.

Pharmicell Co., Ltd.

Pharminox Limited

Phylogica Limited

Plantacor, Inc.

PlantForm Corporation

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Polyphor Ltd.

Precision Biologics, Inc.

Priaxon AG

Prima BioMed Ltd.

ProMetic Life Sciences Inc.

Provectus Biopharmaceuticals, Inc.

Puma Biotechnology, Inc.

Qu Biologics Inc.

Quantum Pharmaceuticals

Quintessence Biosciences, Inc.

Radius Health, Inc.

Recepta Biopharma S.A.

Recombio S.L

Regulon Inc.

Reliance Life Sciences Pvt. Ltd.

Repros Therapeutics Inc.

Rexahn Pharmaceuticals, Inc.

Richter Gedeon Nyrt.

Rigontec GmbH

Sanofi

Sareum Holdings plc

Scancell Holdings Plc

Seattle Genetics, Inc.

Seek

Selvita SA

Sentinel Oncology Limited

Shanghai Henlius Biotech Co., Ltd.

Shenogen Pharma Group Ltd.

Shionogi & Co., Ltd.

Sihuan Pharmaceutical Holdings Group Ltd.

SillaJen Co. Ltd.

Sirnaomics, Inc.

SK Chemicals Co., Ltd.

Soricimed Biopharma Inc.

Sorrento Therapeutics, Inc.

Spectrum Pharmaceuticals, Inc.

Sphaera Pharma Pvt. Ltd.

Sprint Bioscience AB

Starpharma Holdings Limited

Sumitomo Dainippon Pharma Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Supratek Pharma Inc.

Syndax Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

Synthon BV

Takara Bio Inc.

Takeda Oncology

Takeda Pharmaceutical Company Limited

TapImmune Inc.

Terpenoid Therapeutics, Inc.

Tesaro, Inc.

Teva Pharmaceutical Industries Limited

Theraclone Sciences, Inc.

Theracrine, Inc.

Theravectys S.A.

TheRyte Ltd.

TRACON Pharmaceuticals, Inc.

Transgene Biotek Limited

TransTech Pharma, Inc.

Treat U, S.A.

Trojantec ltd.

TVAX Biomedical, Inc.

Vaccinex, Inc.

ValiRx Plc

Vasgen Limited

Vaxeal Holding SA

Vaxil Bio Therapeutics Ltd.

Vaxon Biotech

Verastem, Inc.

Vertex Pharmaceuticals Incorporated

VG Life Sciences, Inc.

Viralytics Ltd.

Virax Holdings Limited

ViroMed Co., Ltd.

Visionary Pharmaceuticals, Inc.

Viventia Biotechnologies Inc.

Welichem Biotech Inc.

Wilex AG

WntResearch AB

Zensun (Shanghai) Sci & Tech Co., Ltd.

ZIOPHARM Oncology, Inc.

Zymeworks Inc.

Zyngenia, Inc.

Breast Cancer Therapeutic Products under Development, Key Players in Breast Cancer Therapeutics, Breast Cancer Pipeline Overview, Breast Cancer Pipeline, Breast Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com